Physician profile
Jerod K Shaw
NPI 1407030836
$5,308.98
in general payments reported to CMS, 2019-2025
15 companies · $991 in 2025
The $991 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $380 · 2021: $664 · 2022: $549 · 2023: $927 · 2024: $1,330 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,247.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,000.12 | 2019-2025 | Proclaim, Eterna |
| Medtronic, INC. | $1,158.32 | 2024-2025 | Intellis Adaptivestim, Synchromedii, Primeadvanced Surescan |
| Boston Scientific Corporation | $306.78 | 2019-2024 | |
| Painteq LLC | $219.89 | 2024 | Painteq |
| Globus Medical, INC. | $150.65 | 2025 | Senza |
| Si-Bone, INC. | $127.44 | 2021-2025 | |
| Relievant Medsystems, INC. | $99.79 | 2022-2023 | Intracept |
| Pacira Pharmaceuticals Incorporated | $67.63 | 2023-2025 | Iovera, Zilretta, Exparel |
| Medtronic USA, INC. | $50.94 | 2019-2020 | |
| Depuy Synthes Sales INC. | $43.46 | 2023-2025 | Monovisc, Orthovisc |
| Bioventus LLC | $21.65 | 2019 | |
| Nalu Medical, INC. | $18.61 | 2021 | |
| Amgen INC. | $18.37 | 2024 | Prolia, Evenity |
| Vertiflex, INC. | $13.07 | 2019 | |
| Pacira Therapeutics, INC. | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerod Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.